R&D News | pharmaphorum

News

Disc maps out US filing for porphyria drug bitopertin

Disc Medicine has charted a route to market for bitopertin, its drug candidate for rare disease erythropoietic protoporphyria (EPP), after meeting with the FDA.

News

Slide showing non-alcoholic fatty liver disease (NAFLD)

Novo Nordisk will file semaglutide for MASH next year

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US

News

Compass Pathways' chief executive Kabir Nath

Compass points to job cuts as it defers trial readouts

Shares in psychedelic drug developer Compass Pathways are sliding today after it announced that it will slash its headcount by 30% and focus all its efforts on its treatment-resistant depre

News

Lexeo shares dip on early data with Alzheimer's gene therapy

Lexeo Therapeutics' gene therapy for Alzheimer's has shown that it can reduce biomarkers of the disease in a small study, including reductions in disease biomarkers.

News

Nasdaq debutante Septerna swells its IPO to $331m

Septerna's protracted initial public offering (IPO) on the Nasdaq has finally reached its conclusion, with the final amount raised topping $331 million.

News

Alpha-9's $175m third-round heads latest biotech financings

Radiopharma start-up Alpha-9 Oncology has closed a sizeable third investment round, heading a list of recent financings that also feature Axonis, Kivu Bio, SynOx, Agomab, and Blue Earth The

Disc maps out US filing for porphyria drug bitopertin

Novo Nordisk will file semaglutide for MASH next year

Compass points to job cuts as it defers trial readouts

Lexeo shares dip on early data with Alzheimer's gene therapy

Nasdaq debutante Septerna swells its IPO to $331m

Alpha-9's $175m third-round heads latest biotech financings

Senju launches first-in-class dry eye disease drug in Japan

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks